AN ECONOMIC PRICE ANALYSIS OF CONVENTIONAL REMISSION THERAPY VS BIOLOGICAL THERAPY FOR RHEUMATOID ARTHRITIS TREATMENT
Rheumatoid arthritis represents the most common inflammatory rheumatism, affecting about 1% of the general population. Inappropriately untreated usually has a progressively aggressive perspective, generating pain and joint inflammation and functional disability. The severity of the disease resul...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universitaria Press Craiova
2019-05-01
|
| Series: | Management & Marketing |
| Subjects: | |
| Online Access: | http://mnmk.ro/en/documents/2019_1/3-10-2-19.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Rheumatoid arthritis represents the most common inflammatory
rheumatism, affecting about 1% of the general population. Inappropriately
untreated usually has a progressively aggressive perspective, generating
pain and joint inflammation and functional disability. The severity of the
disease results from the fact that more than 50% of patients cease their
professional activity in the first 5 years of the disease and 10% of cases
show severe disability in the first two years of evolution. The aim of the study
is to conduct a comparative price analysis between a conventional remission
therapy and a biological therapy for rheumatoid arthritis in Romania.
Biologics are huge financial burden due to their high price, large number of
patients and the considerable budget impact. The data was obtained from
the official pages of National Health Insurance House in Romania up to date
December 2018, and also the algorithm treatment for rheumatoid arthritis is
followed. Conventional remission therapy is 30-100 times cheaper than
biological therapy. The results show that two out of eight INNs (International
non-proprietary name or a generic name) have authorized biosimilars
(similar biological medicinal product) in Romania, despite of bigger number
of authorized biosimilars in EMA (European Medicines Agency) for
rheumatoid arthritis. Biosimilars’ prices have a 19.66-29.68% reduction in
the price of biologics. Introduction of biosimilars on the Romanian market will
lead to significant decrease in reimbursed prices paid by public funds and
thus increase the patients’ access to biological therapy. |
|---|---|
| ISSN: | 1841-2416 |